{"protocolSection":{"identificationModule":{"nctId":"NCT07213154","orgStudyIdInfo":{"id":"STUDY00008502"},"secondaryIdInfos":[{"id":"NCI-2025-02356","type":"REGISTRY","domain":"CTRP (Clinical Trial Reporting Program)"},{"id":"STUDY00008502","type":"OTHER","domain":"Emory University Hospital/Winship Cancer Institute"},{"id":"WINSHIP6407-24","type":"OTHER","domain":"Emory University Hospital/Winship Cancer Institute"},{"id":"P30CA138292","type":"NIH","link":"https://reporter.nih.gov/quickSearch/P30CA138292"}],"organization":{"fullName":"Emory University","class":"OTHER"},"briefTitle":"Optical Imaging Scans for the Diagnosis of Skin Cancer in Patients With Lesions","officialTitle":"Assessment of Novel Label-free Optical Imaging Technology for the Evaluation of Skin Lesions"},"statusModule":{"statusVerifiedDate":"2025-10","overallStatus":"NOT_YET_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2025-10-31","type":"ESTIMATED"},"primaryCompletionDateStruct":{"date":"2026-09-17","type":"ESTIMATED"},"completionDateStruct":{"date":"2027-09-17","type":"ESTIMATED"},"studyFirstSubmitDate":"2025-08-26","studyFirstSubmitQcDate":"2025-10-01","studyFirstPostDateStruct":{"date":"2025-10-08","type":"ESTIMATED"},"lastUpdateSubmitDate":"2025-10-01","lastUpdatePostDateStruct":{"date":"2025-10-08","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Mohammad K. Khan","investigatorTitle":"Principal Investigator","investigatorAffiliation":"Emory University"},"leadSponsor":{"name":"Emory University","class":"OTHER"},"collaborators":[{"name":"National Cancer Institute (NCI)","class":"NIH"}]},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":true,"isUsExport":false},"descriptionModule":{"briefSummary":"This clinical trial studies how well an optical imaging scan called quantitative oblique back-illumination microscopy (qOBM) helps in diagnosing skin cancer in patients with skin lesions. qOBM is a non-invasive procedure that uses red light for illumination, and may work better than no imaging procedures in aiding doctors in diagnosing skin lesions.","detailedDescription":"PRIMARY OBJECTIVE:\n\nI. To perform a first-in-human study to assess the ability of a qOBM handheld device to reliably image skin pathology in-situ and in-vivo.\n\nSECONDARY OBJECTIVES:\n\nI. Characterize a wide variety of lesions including but limited to:\n\nIa. Malignant lesions: basal cell cancers, squamous cell cancers, Merkel cell cancer, melanoma, etc,; Ib. Non-malignant lesions: keloids, surgical scars, actinic keratosis, benign and dysplastic nevi, cysts, lipoma; Ic. Inflammatory conditions: psoriasis, eczema, alopecia, acne, wounds, etc); Id. Characterize pre and post treatment changes in the lesion as well as the surrounding normal tissue stroma (examples, but not limited to: changes to hair follicles, epidermis, dermis, subcutaneous tissue, erector pillae muscles, vessels, nerves, etc); Ie. Correlate optical findings with histological findings for lesions that would have been removed surgically and/or are biopsied (examples, but not limited to: removal of a skin cancer where optical imaging is used to characterize peripheral extent of the lesion as well as depth of penetration, a benign versus malignant lesion, pigmented versus \\[vs\\] non-pigmented lesion, etc).\n\nOUTLINE: Patients are assigned to 1 of 2 groups.\n\nGROUP I: Patients who have skin melanoma and/or suspected dysplastic nevi undergo qOBM optical imaging scan on study. Patients may undergo 2 additional qOBM optical imaging scans at the discretion of the treating physician. After qOBM scans, patients who are diagnosed with skin cancer may proceed to Group II.\n\nGROUP II: Patients with skin cancer who are undergoing standard of care (SOC) radiation therapy (RT) undergo qOBM optical imaging scans prior to- and during or after SOC RT on study. Patients may also undergo qOBM optical imaging scans additional at approximately 1, 6, and 12 months after completion of SOC RT at the discretion of the treating physician."},"conditionsModule":{"conditions":["Malignant Skin Neoplasm","Skin Disorder","Skin Neoplasm"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["NA"],"designInfo":{"allocation":"NON_RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"DIAGNOSTIC","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":10,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Group I (qOBM)","type":"EXPERIMENTAL","description":"Patients who have skin melanoma and/or suspected dysplastic nevi undergo qOBM optical imaging scan on study. Patients may undergo 2 additional qOBM optical imaging scans at the discretion of the treating physician. After qOBM scans, patients who are diagnosed with skin cancer may proceed to Group II.","interventionNames":["Procedure: Quantitative Oblique Back-Illumination Microscopy"]},{"label":"Group II (qOBM, SOC RT)","type":"EXPERIMENTAL","description":"GROUP II: Patients with skin cancer who are undergoing SOC RT undergo qOBM optical imaging scans prior to- and during or after SOC RT on study. Patients may also undergo qOBM optical imaging scans additional at approximately 1, 6, and 12 months after completion of SOC RT at the discretion of the treating physician.","interventionNames":["Procedure: Quantitative Oblique Back-Illumination Microscopy","Radiation: Radiation Therapy"]}],"interventions":[{"type":"PROCEDURE","name":"Quantitative Oblique Back-Illumination Microscopy","description":"Undergo qOBM","armGroupLabels":["Group I (qOBM)","Group II (qOBM, SOC RT)"],"otherNames":["qOBM"]},{"type":"RADIATION","name":"Radiation Therapy","description":"Undergo SOC RT","armGroupLabels":["Group II (qOBM, SOC RT)"],"otherNames":["Cancer Radiotherapy","Energy Type","ENERGY_TYPE","Irradiate","Irradiated","Irradiation","Radiation","Radiation Therapy, NOS","Radiotherapeutics","Radiotherapy","RT","Therapy, Radiation"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"qOBM Clinical Assessment","description":"Assessing the application of quantitative oblique back-illumination microscopy (qOBM) to assess skin pathology. Analysis will be descriptive in nature (e.g., appearance of cells in the epidermis, dermis, and basal junction). Quantitative analysis will include extracting image features such as mean, standard deviation, and kurtosis of the phase values; entropy, fractal dimension, gray level co-occurrence matrix, and other mathematical image features. Radiation Therapy Oncology Group (RTOG) Acute Radiation Morbidity Scoring Criteria (Skin) Grade 0. No change over baseline, Grade 1. Follicular, faint or dull erythema/epilation/dry desquamation/decreased sweating, Grade 2. Tender or bright erythema, patchy moist desquamation/moderate edema, Grade 3. Confluent, moist desquamation other than skin folds, pitting edema, Grade 4. Ulceration, hemorrhage, necrosis","timeFrame":"Up to 12 months"}],"secondaryOutcomes":[{"measure":"Usability of the qOBM Device","description":"Will collect information regarding the usability of the device, including how ergonomic it is, ideal for factors for acquiring images and visualizing structures in real time. Quantitative analysis will include extracting image features such as mean, standard deviation, and kurtosis of the phase values; entropy, fractal dimension, gray level co-occurrence matrix, and other mathematical image features. Differences between similar diagnoses vs adjacent normal skin will be evaluated using a two-sided t-test.","timeFrame":"Up to 12 months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or Female\n* Candidate with skin lesions\n* Signed study-specific informed consent prior to study entry\n* â‰¥ 18 years old\n\nExclusion Criteria:\n\n* Prior surgery or radiotherapy to the area to be treated","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Mohammad K. Khan, MD, PhD, MS, FACRO, FACR, DABR","role":"CONTACT","phone":"404-778-3473","email":"m.k.khan@emory.edu"}],"overallOfficials":[{"name":"Mohammad K. Khan, MD, PhD, MS, FACRO, FACR, DABR","affiliation":"Emory University Hospital/Winship Cancer Institute","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Emory University Hospital Midtown","city":"Atlanta","state":"Georgia","zip":"30308","country":"United States","contacts":[{"name":"Tiffaney Roundtree","role":"CONTACT","email":"tiffaney.laquinta.roundtree@emory.edu"},{"name":"Mohammad K. Khan, MD, PhD, MS, FACRO, FACR, DABR","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":33.749,"lon":-84.38798}},{"facility":"Emory University Hospital/Winship Cancer Institute","city":"Atlanta","state":"Georgia","zip":"30322","country":"United States","contacts":[{"name":"Tiffaney K. Roundtree","role":"CONTACT","email":"tiffaney.laquinta.roundtree@emory.edu"},{"name":"Mohammad K. Khan, MD, PhD, MS, FACRO, FACR, DABR","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":33.749,"lon":-84.38798}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-10-31"},"conditionBrowseModule":{"meshes":[{"id":"D012878","term":"Skin Neoplasms"},{"id":"D012871","term":"Skin Diseases"}],"ancestors":[{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D017437","term":"Skin and Connective Tissue Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D011878","term":"Radiotherapy"},{"id":"D011827","term":"Radiation"}],"ancestors":[{"id":"D013812","term":"Therapeutics"},{"id":"D055585","term":"Physical Phenomena"}]}},"hasResults":false}
